Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06459973 · ClinicalTrials.gov registry record · Phase 1

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by MediLink Therapeutics (Suzhou) Co..

Recruiting
Registry status
Phase 1
Development phase
252
Enrollment target
20
Study locations

NCT06459973 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 252 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 19 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06459973, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..

RECRUITING
Registry status
Phase 1
Development phase
252 participants
Enrollment target
20
Study locations

Study Summary

This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG intravenous (IV) infusion

Study Locations (20)

Henan

  • Anyang Cancer Hospital - Anyang
  • Henan Cancer Hospital - Zhengzhou

Colorado

  • Sarah Cannon Research Institute (SCRI)- Denver - Denver

Connecticut

  • Yale Cancer Center - New Haven

Florida

  • Florida Cancer Specialists - Lake Mary - Lake Mary

Kentucky

  • Norton Cancer Institute - Louisville

Missouri

  • Washington University School of Medicine - Center for advanced Medicine - St Louis

Nevada

  • Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley - Las Vegas

New Mexico

  • Southwest Women's Oncology - Albuquerque

Trial Details

FieldValue
Enrollment Target 252 participants
Start Date 2024-06-04
Est. Completion 2030-07-31
Phase Phase 1

Sponsor

MediLink Therapeutics (Suzhou) Co.

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06459973

The ClinicalTrials.gov registry entry for NCT06459973 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (28% higher). The listed sponsor is MediLink Therapeutics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which intravenous (IV) infusion is the first listed.

NCT06459973 reports 20 study locations spanning 19 distinct geographic areas - top geographies include Henan, Colorado, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06459973 about?

NCT06459973 is a clinical study titled "A Clinical Study of YL205 in Patients With Advanced Solid Tumors". This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

What is the current status of trial NCT06459973?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 252 participants. The study started on 2024-06-04. Estimated completion is 2030-07-31.

What conditions does trial NCT06459973 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06459973?

The interventions under investigation include: intravenous (IV) infusion (DRUG).

Who is sponsoring clinical trial NCT06459973?

This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06459973 being conducted?

This trial has 20 study locations across Colorado, Connecticut, Florida, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.